Last reviewed · How we verify

Shanghai Bovax Biotechnology Co., Ltd. — Portfolio Competitive Intelligence Brief

Shanghai Bovax Biotechnology Co., Ltd. pipeline: 0 marketed, 0 filed, 1 Phase 3, 1 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 1 Phase 3 1 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Active Comparator: GARDASIL ®9 Active Comparator: GARDASIL ®9 phase 3 Recombinant HPV vaccine Human papillomavirus (HPV) types 6, 11, 16, 18, 31, 33, 45, 52, 58 Oncology / Immunology / Infectious Disease

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Boston Medical Center · 1 shared drug class
  2. Erasmus Medical Center · 1 shared drug class
  3. GlaxoSmithKline · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Shanghai Bovax Biotechnology Co., Ltd.:

Cite this brief

Drug Landscape (2026). Shanghai Bovax Biotechnology Co., Ltd. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/shanghai-bovax-biotechnology-co-ltd. Accessed 2026-05-17.

Related